大同集團(00544.HK)擬發行5802.21萬股新股及本金額4500萬港元的可轉債
格隆匯4月21日丨大同集團(00544.HK)公佈,於2025年4月20日,公司與各個認購人分別訂立該等認購協議,據悉,公司擬分別向認購人A、認購人B及認購人C配發1934.07萬股,每股配售價爲0.04801港元,較4月17日收市價折價約19.98%。所得款項淨額約252萬港元將擬用於(i)償還集團債務;及(ii)爲集團的營運資金提供資金。
同日,公司擬分別向三名認購人發行本金額1500萬港元的可轉債,可按每股轉換股份0.04801港元之換股價轉換爲轉換股份。可換股債券認購所得款項淨額約4067萬港元將擬用於(i)償還集團債務;及(ii)爲集團的營運資金提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.